DAWN
Day One Biopharmaceuticals Inc

1,957
Mkt Cap
$1.12B
Volume
1.46M
52W High
$13.20
52W Low
$5.64
PE Ratio
-10.17
DAWN Fundamentals
Price
$10.60
Prev Close
$10.65
Open
$10.63
50D MA
$10.63
Beta
1.11
Avg. Volume
2.92M
EPS (Annual)
-$1.04
P/B
2.47
Rev/Employee
$888,662.92
$523.56
Loading...
Loading...
News
all
press releases
Research Analysts Issue Forecasts for DAWN Q1 Earnings
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at HC Wainwright decreased their Q1 2026 EPS estimates for Day One Biopharmaceuticals in a research report issued to...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to Hold at Zacks Research
Zacks Research downgraded Day One Biopharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday...
MarketBeat·3d ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Announces Earnings Results, Misses Expectations By $0.04 EPS
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·4d ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down After Earnings Miss
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down on Disappointing Earnings...
MarketBeat·4d ago
News Placeholder
Wedbush Forecasts Strong Price Appreciation for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock
Wedbush raised their price objective on shares of Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an "outperform" rating in a research report on Wednesday...
MarketBeat·4d ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $22.00 at HC Wainwright
HC Wainwright dropped their price objective on Day One Biopharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a report on Wednesday...
MarketBeat·4d ago
News Placeholder
Needham & Company LLC Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $17.00
Needham & Company LLC lowered their price target on shares of Day One Biopharmaceuticals from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday...
MarketBeat·4d ago
News Placeholder
Day One Biopharmaceuticals Q4 Earnings Call Highlights
Day One Biopharmaceuticals (NASDAQ:DAWN) detailed accelerating commercial momentum for OJEMDA and outlined several upcoming clinical catalysts during its fourth-quarter and full-year 2025 earnings...
MarketBeat·5d ago
News Placeholder
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -19.98% and +11.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Day One Biopharmaceuticals, Inc. $DAWN Shares Sold by NEOS Investment Management LLC
NEOS Investment Management LLC decreased its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 84.3% during the 3rd quarter, according to the company in its most recent...
MarketBeat·8d ago
<
1
2
...
>

Latest DAWN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.